Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-based Antiretroviral Therapy

被引：3
作者：
Johnson, Kelly A. [1 ]
Okochi, Hideaki [1 ]
Arreguin, Mireya [1 ]
Watabe, Joseph [1 ]
Glidden, David, V [2 ]
Chattopadhyay, Anindita [1 ]
Imbert, Elizabeth [1 ]
Hickey, Matthew D. [1 ]
Gandhi, Monica [1 ]
Spinelli, Matthew [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 05期
关键词：
tenofovir alafenamide; adherence; viral suppression; point-of-care monitoring; HIV; ADHERENCE;
D O I：
10.1093/cid/ciac828
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We found that urine tenofovir (TFV) levels >1500 ng/mL strongly predict virologic suppression among people with human immunodeficiency virus taking tenofovir alafenamide (odds ratio, 5.66; 95% confidence interval, 1.59-20.14; P = .007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate will support adherence monitoring for patients on all TFV-based antiretrovirals.
引用
收藏
页码：930 / 933
页数：4
相关论文
共 50 条
  • [1] Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
    Ray, Adrian S.
    Fordyce, Marshall W.
    Hitchcock, Michael J. M.
    ANTIVIRAL RESEARCH, 2016, 125 : 63 - 70
  • [2] No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide
    Johnson, Kelly A.
    Okochi, Hideaki
    Glidden, David, V
    Gandhi, Monica
    Spinelli, Matthew
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (01) : 57 - 60
  • [3] Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy
    Alexandra Sjaarda
    Andrew Bernstein
    Andrew Sparks
    Saghar Saber
    Marc Siegel
    Infection, 2022, 50 : 407 - 412
  • [4] Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
    Seo, Jun-Won
    Kim, Kichun
    Jun, Kang Il
    Kang, Chang Kyung
    Moon, Song Mi
    Song, Kyoung-Ho
    Bang, Ji-Hwan
    Kim, Eu Suk
    Kim, Hong Bin
    Park, Sang Won
    Kim, Nam Joong
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Oh, Myoung-don
    INFECTION AND CHEMOTHERAPY, 2020, 52 (03) : 381 - 388
  • [5] Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy
    Sjaarda, Alexandra
    Bernstein, Andrew
    Sparks, Andrew
    Saber, Saghar
    Siegel, Marc
    INFECTION, 2022, 50 (02) : 407 - 412
  • [6] Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)
    Damas, Jose
    Munting, Aline
    Fellay, Jacques
    Haerry, David
    Marzolini, Catia
    Tarr, Philip E.
    Steffen, Ana
    Braun, Dominique L.
    Stoeckle, Marcel
    Bernasconi, Enos
    Tshikung, Olivier Nawej
    Fux, Christoph A.
    Darling, Katharine E. A.
    Beguelin, Charles
    Wandeler, Gilles
    Cavassini, Matthias
    Surial, Bernard
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (04) : 990 - 998
  • [7] Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections
    Castillo-Mancilla, Jose R.
    Morrow, Mary
    Coyle, Ryan P.
    Coleman, Stacey S.
    Gardner, Edward M.
    Zheng, Jia-Hua
    Ellison, Lucas
    Bushman, Lane R.
    Kiser, Jennifer J.
    Mawhinney, Samantha
    Anderson, Peter L.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 (08) : 1335 - 1342
  • [8] Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques
    Massud, Ivana
    Cong, Mian-Er
    Ruone, Susan
    Holder, Angela
    Dinh, Chuong
    Nishiura, Kenji
    Khalil, George
    Pan, Yi
    Lipscomb, Jonathan
    Johnson, Ryan
    Deyounks, Frank
    Rooney, James F.
    Babusis, Darius
    Park, Yeojin
    McCallister, Scott
    Callebaut, Christian
    Heneine, Walid
    Garcia-Lerma, J. Gerardo
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 (11) : 1826 - 1833
  • [9] Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection
    Stalter, Randy M.
    Baeten, Jared M.
    Donnell, Deborah
    Spinelli, Matthew A.
    Glidden, David, V
    Rodrigues, Warren C.
    Wang, Guohong
    Vincent, Michael
    Mugo, Nelly
    Mujugira, Andrew
    Marzinke, Mark
    Hendrix, Craig
    Gandhi, Monica
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (03) : 486 - 489
  • [10] Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With Human Immunodeficiency Virus Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF)
    Coyle, Ryan P.
    Morrow, Mary
    Mann, Sarah C.
    Mainella, Vincent
    Ellis, Samuel L.
    Schwab, Stefanie
    Coppinger, Corwin
    Barker, Nicholas
    Ellison, Lucas
    Zheng, Jia-Hua
    Al Zuabi, Subhi
    Alpert, Pamela E.
    Carnes, Tony C.
    Buffkin Jr, D. Eric
    Chai, Peter R.
    Bushman, Lane R.
    Kiser, Jennifer J.
    MaWhinney, Samantha
    Brooks, Kristina M.
    Anderson, Peter L.
    Castillo-Mancilla, Jose R.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (05) : 1233 - 1241
12345